Suppr超能文献

尿道注射治疗压力性尿失禁:右旋糖酐/透明质酸共聚物的长期疗效

Urethral injection for stress urinary incontinence: long-term results with dextranomer/hyaluronic acid copolymer.

作者信息

Stenberg A M, Larsson G, Johnson P

机构信息

Department of Gynecology, Enköping Hospital, Box 908, SE-745 25 Enköping, Sweden.

出版信息

Int Urogynecol J Pelvic Floor Dysfunct. 2003 Nov;14(5):335-8; discussion 338. doi: 10.1007/s00192-003-1075-y. Epub 2003 Sep 13.

Abstract

Urethral injection is a convenient, minimally invasive means of treating stress urinary incontinence (SUI). We present long-term follow-up data from 20 patients originally recruited in 1994-95 (mean age 67 years) to receive urethral injection with dextranomer/hyaluronic acid (Dx/HA) copolymer. The majority of patients had failed previous therapy for SUI. If the first injection was unsuccessful, up to two further injections were offered. Only 3 patients (15%) failed to show a response to treatment. Sixteen women were reassessed during 2001 (4 had died of causes unrelated to the study treatment). A sustained response throughout the follow-up period was reported in 9/16 patients (57%), with incontinence recurring in just 4 (25%). None of the 7 patients with persistent or recurrent incontinence were cured by subsequent treatments, including surgery. In conclusion, urethral injection with Dx/HA copolymer offers promising long-term efficacy in the treatment of SUI, regardless of old age or failure to respond to previous therapy.

摘要

尿道注射是一种治疗压力性尿失禁(SUI)的便捷、微创方法。我们展示了20例于1994 - 1995年招募的患者(平均年龄67岁)接受葡聚糖/透明质酸(Dx/HA)共聚物尿道注射的长期随访数据。大多数患者先前的SUI治疗均告失败。若首次注射未成功,最多可再进行两次注射。仅3例患者(15%)对治疗无反应。2001年对16名女性进行了重新评估(4名因与研究治疗无关的原因死亡)。9/16例患者(57%)在整个随访期间报告有持续反应,仅有4例(25%)尿失禁复发。7例持续性或复发性尿失禁患者中,包括手术在内的后续治疗均未治愈。总之,无论患者年龄多大或对先前治疗有无反应,Dx/HA共聚物尿道注射在治疗SUI方面都具有良好的长期疗效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验